Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma.

@article{Thomas2009PhaseIT,
  title={Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma.},
  author={Melanie Byrne Thomas and Jeffrey S. Morris and Romil Chadha and Michiko Iwasaki and Harmeet Kaur and Edward B Lin and Ahmed Kaseb and Katrina Glover and Marta Davila and James L Abbruzzese},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2009},
  volume={27 6},
  pages={843-50}
}
PURPOSE The study objective was to determine the proportion of patients with hepatocellular carcinoma (HCC) treated with the combination of bevacizumab (B) and erlotinib (E) who were alive and progression free at 16 weeks (16-week progression-free survival [PFS16]) of continuous therapy. Secondary objectives included response rate, median PFS, survival, and toxicity. PATIENTS AND METHODS Patients who had advanced HCC that was not amenable to surgical or regional therapies, up to one prior… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 133 extracted citations

Similar Papers

Loading similar papers…